|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2cm显示文摘AIM:To analyze the long-term prognosis in a cohort of western cirrhotic patients with single hepatocellular carcinoma treated with ethanol injection.METHODS:One-hundred forty-eight patients with solitary hepatocellular carcinoma were enrolled.The tumor diameter was lower than 2 cm in 47 patients but larger in the remaining 101 patients.The impact of some pretreatment clinical and laboratory parameters and of tumor recurrence on patients' survival was assessed.RESULTS:Among the pre-treatment parameters,only a tumor diameter of less than 2 cm was an independent prognostic factor of survival.The occurrence of new nodules in other liver segments and the neoplastic portal invasion were linked to a poorer prognosis at univariate analysis.Patients with a single hepatocellular carcinoma smaller than 2 cm showed a better 5-year cumulativesurvival(73.0% vs 47.9%)(P = 0.009),3-year local recurrence rate(29.1% vs 51.5%)(P = 0.011),and 5-year distant intrahepatic recurrence rate(52.9% vs 62.8%)(P = 0.054) compared to patients with a larger tumor.CONCLUSION:The 5-year survival rate of patients with single hepatocellular carcinoma < 2 cm undergoing ethanol injection is excellent and comparable to that achieved using radiofrequency ablation. | Maurizio Pompili Erica Nicolardi Valeria Abbate Luca Miele Laura Riccardi Marcello Covino Nicoletta De Matthaeis Antonio Grieco Raffaele Landolfi Gian Ludovico Rapaccini | 2011 | World Journal of Gastroenterology2011，17，26： | 6 |
| 2 | Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development显示文摘 | Maria Assunta Zocco Enrico Di Stasio Raimondo De Cristofaro Marialuisa Novi Maria Elena Ainora Francesca Ponziani Laura Riccardi Stefano Lancellotti Angelo Santoliquido Roberto Flore Maurizio Pompili Gian Lodovico Rapaccini Paolo Tondi Giovanni Battista G | 2009 | Journal of Hepatology2009，，4： | 5 |
| 3 | Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C显示文摘Hepatitis C virus(HCV) infection has been a global health problem for decades, due to the high number of infected people and to the lack of effective and welltolerated therapies. In the last 3 years, the approval of new direct acting antivirals characterized by high rates of virological clearance and excellent tolerability has dramatically improved HCV infection curability, especially for patients with advanced liver disease and for liver transplant recipients. Long-term data about the impact of the new direct acting antivirals on liver fibrosis and liver disease-related outcomes are not yet available, due to their recent introduction. However, previously published data deriving from the use of pegylatedinterferon and ribavirin lead to hypothesizing that we are going to observe, in the future, a reduction in mortality and in the incidence of hepatocellular carcinoma, as well as a regression of fibrosis for people previously affected by hepatitis C. In the liver transplant setting, clinical improvement has already been described after treatment with the new direct acting antivirals, which has often led to patients delisting. In the future, this may hopefully reduce the gap between liver organ request and availability, probably expanding liver transplant indications to other clinical conditions. Therefore, these new drugs are going to change the natural history of HCV-related liver disease and the epidemiology of HCV infection worldwide. However, the global consequences will depend on treatment accessibility and on the number of countries that could afford the use of the new direct acting antivirals. | Francesca Romana Ponziani Francesca Mangiola Cecilia Binda Maria Assunta Zocco Massimo Siciliano Antonio Grieco Gian Lodovico Rapaccini Maurizio Pompili Antonio Gasbarrini | 2017 | World Journal of Hepatology2017，9，7： | 3 |
| 4 | Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study显示文摘 | Alessandro Vitale Patrizia Burra Anna Chiara Frigo Franco Trevisani Fabio Farinati Gaya Spolverato Michael Volk Edoardo G. Giannini Francesca Ciccarese Fabio Piscaglia Gian Lodovico Rapaccini Mariella Di Marco Eugenio Caturelli Marco Zoli Franco Borzio Gi | 2014 | Journal of Hepatology2014，，： | 2 |
| 5 | Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development显示文摘 | Maria Assunta Zocco Enrico Di Stasio Raimondo De Cristofaro Marialuisa Novi Maria Elena Ainora Francesca Ponziani Laura Riccardi Stefano Lancellotti Angelo Santoliquido Roberto Flore Maurizio Pompili Gian Lodovico Rapaccini Paolo Tondi Giovanni Battista G | 2009 | Journal of Hepatology2009，，4： | 2 |
| 6 | Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease显示文摘 | Luca Miele Venanzio Valenza Giuseppe La Torre Massimo Montalto Giovanni Cammarota Riccardo Ricci Roberta Mascianà Alessandra Forgione Maria L. Gabrieli Germano Perotti Fabio M. Vecchio Gianlodovico Rapaccini Giovanni Gasbarrini Chris P. Day Antonio Grieco | 2009 | Hepatology2009，，6： | 2 |
| 7 | Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents显示文摘 | Alfredo Papa Carla Felice Manuela Marzo Gianluca Andrisani Alessandro Armuzzi Marcello Covino Giammarco Mocci Daniela Pugliese Italo De Vitis Antonio Gasbarrini Gian Lodovico Rapaccini Luisa Guidi | 2012 | Journal of Crohn’s and Colitis2012，，： | 2 |
| 8 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 2 |
| 9 | Portal vein thrombosis complicating hepatocellular carcinoma: value of ultrasound-guided fine needle biopsy of the thrombus in the therapeutic management 显示文摘 | Cedrone JV Rapaccini GL Pompili M | 1996 | Liver1996，16，2： | 1 |
| 10 | Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population显示文摘 | Alessandro Cucchetti Franco Trevisani Matteo Cescon Giorgio Ercolani Fabio Farinati Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Caturelli Maria Chiaramonte Antonio D | 2012 | Journal of Hepatology2012，，5： | 1 |
| 11 | Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging显示文摘 | A. Gatto A. M. Gaetano M. Giuga M. Ciresa L. Siciliani L. Miele L. Riccardi F. Pizzolante G. L. Rapaccini A. Gasbarrini F. Giuliante F. M. Vecchio M. Pompili L. Bonomo | 2013 | Abdominal Imaging2013，，4： | 1 |
| 12 | Early prediction of response to Sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound显示文摘 | Zocco Maria Assunta Garcovich Matteo Lupascu Andrea Di Stasio Enrico Roccarina Davide Annicchiarico Brigida Elenora Riccardi Laura Ainora Maria Elena Ponziani Francesca Caracciolo Gianluigi Rapaccini Gian Lodovico Landolfi Raffaele Siciliano Massimo Pompi | 2013 | Journal of Hepatology2013，，： | 1 |
| 13 | Percutaneous ablative treatments of hepatocellular carcinoma 显示文摘 | Rapaccini GL | 2015 | Hepatology2015，61，5： | 1 |
| 14 | Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice:Serum sodium predicts survival显示文摘AIM: To assess the prognostic role of baseline clinical, biochemical and radiological characteristics of patients with hepatocellular carcinoma(HCC) treated with the first transarterial chemoembolization(TACE) procedure.METHODS: Patients with HCC treated with conventional TACE in a tertiary care setting from 1997 to 2008 were retrospectively reviewed. Predictors of survival were identified using the Cox proportional regression model.RESULTS: Two hundred and seventy patients wereincluded. Median age was 66 years, 81% were male, 58% were HCV-positive, 18% hepatitis B surface antigen-positive, 64% had a Child A status, 40% patients had a largest nodule diameter ≥ 5 cm and 32% had more than 3 tumor nodules. Median overall survival of the whole cohort was 25 mo(95%CI: 21.8-28.2) and the 1-, 2- and 3-year probability of survival was 80%, 50% and 31%, respectively. Non-tumor segmental portal vein thrombosis(HR = 1.76, 95%CI: 1.22-2.54), serum sodium(HR = 1.65, 95%CI: 1.25-2.18), diameter of largest nodule(HR = 1.59, 95%CI: 1.22-2.091), number of nodules(HR = 1.41, 95%CI: 1.06-1.88), alpha-fetoprotein(HR = 1.35, 95%CI: 1.03-1.76) and alkaline phosphatase(HR = 1.33, 95%CI: 1.01-1.74) were independent prognostic factors for overall survival on multivariate analysis.CONCLUSION: The inclusion of serum sodium alongside the already known prognostic factors may allow a better prognostic definition of patients with HCC as candidates for conventional TACE. | Marco Biolato Luca Miele Vittoria Vero Simona Racco Carmine Di Stasi Roberto Iezzi Andrea Zanché Maurizio Pompili Gian Ludovico Rapaccini Giuseppe La Torre Antonio Gasbarrini Antonio Grieco | 2014 | World Journal of Gastroenterology2014，20，25： | 1 |
| 15 | Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study显示文摘 | Alessandro Vitale Rafael Ramirez Morales Giacomo Zanus Fabio Farinati Patrizia Burra Paolo Angeli Anna Chiara Frigo Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Catur | 2011 | Lancet Oncology2011，，7： | 1 |
| 16 | The changing scenario of hepatocellular carcinoma over the last two decades in Italy显示文摘 | Valentina Santi Daniela Buccione Antonio Di Micoli Gianluca Fatti Marta Frigerio Fabio Farinati Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Caturelli Maria Chiaramon | 2011 | Journal of Hepatology2011，，2： | 1 |
| 17 | Liver transplantation显示文摘 | Pompili M Mirante VG Rapaccini GL | 2004 | Ann Ital Med Int2004，19，1： | 1 |
| 18 | Life cycle assessment of electricity production from poplar energy crops compared with conventional fossil fuels显示文摘 | Rafaschieri A Rapaccini M Manfrida G | 1999 | Energy Conversion and Management1999，40，14： | 1 |
| 19 | The changing scenario of hepatocellular carcinoma over the last two decades in Italy显示文摘 | Valentina Santi Daniela Buccione Antonio Di Micoli Gianluca Fatti Marta Frigerio Fabio Farinati Paolo Del Poggio Gianludovico Rapaccini Maria Anna Di Nolfo Luisa Benvegnù Marco Zoli Franco Borzio Edoardo Giovanni Giannini Eugenio Caturelli Maria Chiaramon | 2011 | Journal of Hepatology2011，，2： | 1 |
| 20 | Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation显示文摘 | Maurizio Pompili Claudio Maurizio Pacella Giampiero Francica Mario Angelico Giuseppe Tisone Paolo Craboledda Erica Nicolardi Gian Ludovico Rapaccini Giovanni Gasbarrini | 2009 | European Journal of Radiology2009，，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员